By Sabela Ojea
BioAge Labs said it is discontinuing a Phase 2 clinical trial evaluating its drug azelaprag to treat obesity.
The clinical-stage biopharmaceutical company on Friday said it is also discontinuing the trial for the combination of azelaprag with tirzepatide after some subjects receiving azelaprag were diagnosed with liver transaminitis.
No transaminase elevations were observed in the tirzepatide only treatment group, the company added.
"While this outcome is a significant disappointment, we remain encouraged by azelaprag's promising preclinical and Ph1b efficacy profile," Chief Executive Kristen Fortney said.
The trial of azelaprag and in combination with tirzepatide was expected to enroll around 220 individuals with obesity aged 55 years and older.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
December 06, 2024 17:15 ET (22:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.